BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Siyahian A, Malik SU, Mushtaq A, Howe CL, Majeed A, Zangeneh T, Iftikhar S, Habib S, Zahid U, Riaz IB, Warraich Z, Faridi W, Anwer F. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 2018;24:1483-9. [PMID: 29545185 DOI: 10.1016/j.bbmt.2018.02.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Wu Y, Chen Y, Zhu P, Ye B, Lu Y, Shi J, Tan Y, Zhao Y, Yu J, Lai X, Lan J, Si T, Ni L, Huang H, Luo Y. Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantatio:a multi-institutional experience from an HBV endemic area. Ann Hematol. [DOI: 10.1007/s00277-021-04730-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shen Y, Qi J, Wang Y, Chen J, Fan Y, Wang Y, Wu D, Xu Y. Hepatitis B immunoglobulin (HBIG) combined with long-term entecavir prophylaxis for hepatitis B virus infection in allogeneic hematopoietic stem cell transplantation with hepatitis B surface antigen-positive donors. Leuk Lymphoma 2021;62:2284-7. [PMID: 33733985 DOI: 10.1080/10428194.2021.1901095] [Reference Citation Analysis]
3 Buzo BF, Ramos JF, Marques Rossetti RA, Salles N, Mendrone-Júnior A, Rocha V, de Seixas Santos Nastri AC. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center. Transpl Infect Dis 2020;22:e13243. [PMID: 31901206 DOI: 10.1111/tid.13243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Bruno JJ, Tverdek FP. Antimicrobial Prophylaxis in High-Risk Oncology Patients. Oncologic Critical Care 2020. [DOI: 10.1007/978-3-319-74588-6_27] [Reference Citation Analysis]
5 Pawłowska M, Flisiak R, Gil L, Horban A, Hus I, Jaroszewicz J, Lech-marańda E, Styczyński J. Profilaktyka reaktywacji zakażeń HBV – rekomendacje grupy roboczej profilaktyki reaktywacji HBV. Acta Haematologica Polonica 2019;50:192-198. [DOI: 10.2478/ahp-2019-0031] [Reference Citation Analysis]
6 Gentile G, Antonelli G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019;11. [PMID: 31717647 DOI: 10.3390/v11111049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
7 Pawłowska M, Flisiak R, Gil L, Horban A, Hus I, Jaroszewicz J, Lech-Marańda E, Styczyński J. Prophylaxis of hepatitis B virus (HBV) infection reactivation - recommendations of the Working Group for prevention of HBV reactivation. Clin Exp Hepatol 2019;5:195-202. [PMID: 31598555 DOI: 10.5114/ceh.2019.87631] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
8 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 124] [Article Influence: 37.7] [Reference Citation Analysis]
9 Bruno JJ, Tverdek FP. Antimicrobial Prophylaxis in High-Risk Oncology Patients. Oncologic Critical Care 2019. [DOI: 10.1007/978-3-319-74698-2_27-2] [Reference Citation Analysis]
10 Bruno JJ, Tverdek FP. Antimicrobial Prophylaxis in High-Risk Oncology Patients. Oncologic Critical Care 2019. [DOI: 10.1007/978-3-319-74698-2_27-1] [Reference Citation Analysis]